FDA approved Baxfendy for adults with uncontrolled hypertension, introducing a new drug class in a large and competitive market.
The FDA has approved Baxfendy (baxdrostat; AstraZeneca) for adults with hypertension who remain inadequately controlled on other antihypertensive agents, according to a May 18 announcement. The decision introduces the first approved aldosterone synthase inhibitor for this setting, adding a new option to a treatment market where many patients still fail to reach blood pressure targets despite multidrug therapy.¹⁻³
For executives and biopharma leaders, the approval is notable less for headline novelty than for what it may signal about commercial and development opportunities in hypertension, a category that has seen limited mechanistic innovation in recent decades.
“We have been waiting for an innovative medication like Baxfendy for hypertension for many years. Its novel way of lowering blood pressure has the potential to transform clinical practice by targeting a root cause of persistently uncontrolled hypertension,” said Bryan Williams, MD, chair of medicine at University College London and primary investigator of the pivotal program, in a press release. “In addition, the nearly double-digit placebo-adjusted systolic blood pressure reduction achieved with Baxfendy is exciting and clinically meaningful for clinicians and patients. Epidemiological data indicate that a 10 mmHg decrease in systolic blood pressure is associated with a roughly 20% lower risk of serious cardiovascular events.”1
The approved indication is use in combination with other antihypertensive drugs to lower blood pressure in adults not adequately controlled on other agents. Recommended dosing is 2 mg once daily, with 1 mg once daily suggested for patients at increased risk of hyperkalemia or hyponatremia.1
The regulatory decision was based on the phase 3 BaxHTN trial, which enrolled 796 patients with uncontrolled or resistant hypertension already receiving background therapy that included diuretics. Participants were randomly assigned in a 1:1:1 ratio to Baxfendy 2 mg, Baxfendy 1 mg, or placebo during a 12-week double-blind period. The primary endpoint was change from baseline in seated systolic blood pressure at week 12.¹
At week 12, mean seated systolic blood pressure fell by 15.7 mmHg in the 2 mg group and 14.5 mmHg in the 1 mg group, compared with 5.8 mmHg with placebo, the company said. Placebo-adjusted reductions were 9.8 mmHg for the 2 mg dose and 8.7 mmHg for the 1 mg dose, both statistically significant. Results were reported to be consistent in uncontrolled and treatment-resistant subgroups.¹
The approval lands in a therapeutic area defined by scale and residual risk. The World Health Organization has described hypertension as one of the leading modifiable contributors to death and disability globally.² In US practice, resistant and uncontrolled hypertension remain persistent problems even with established generic options and guideline-based care.³
Baxfendy targets aldosterone synthase, the enzyme responsible for aldosterone production in the adrenal gland. Aldosterone promotes sodium retention and contributes to elevated blood pressure, while also being linked to cardiovascular and kidney risk.
The mechanism differentiates baxdrostat from mineralocorticoid receptor antagonists, which act downstream. Prior clinical work suggested the agent could suppress aldosterone without materially affecting cortisol across studied doses.⁴
That mechanism may help explain strategic interest in broader cardiorenal uses. Baxfendy is also under investigation in primary aldosteronism, chronic kidney disease with hypertension, and heart failure prevention settings, including combination development with dapagliflozin.
From a clinical and business standpoint, the blood pressure effect size appears relevant, particularly in a population already treated with multiple agents. Earlier data published in The New England Journal of Medicine showed activity in treatment-resistant hypertension, and the phase 3 Bax24 program later reported reductions in ambulatory blood pressure in resistant disease.1,4
Still, market uptake will likely depend on where prescribers position the drug relative to existing low-cost therapies, how payers define inadequately controlled hypertension, and whether real-world persistence is affected by laboratory monitoring requirements. Label warnings call for baseline and periodic monitoring of potassium and sodium, reflecting the main on-target safety considerations.
In pooled placebo-controlled trials cited in the announcement, the most frequently reported adverse reactions included hyperkalemia, hypotension, hyponatremia, dizziness, and muscle spasms. Hyperkalemia occurred in 6.6% of patients on 1 mg and 10.2% on 2 mg. Hyponatremia was reported in 2.1% and 3.2%, respectively.
The approval also has pipeline implications. AstraZeneca obtained Baxfendy through its 2023 acquisition of CinCor Pharma, tying the asset to a broader cardiorenal strategy.¹ Whether baxdrostat becomes a meaningful franchise will depend not only on antihypertensive prescribing but on outcome-oriented expansion into adjacent indications where aldosterone biology may have a clearer role in disease progression.
Important unanswered questions remain. The current approval is based on blood pressure reduction rather than cardiovascular outcomes, and longer-term evidence will matter for differentiation in a mature market. Wider use may also hinge on how clinicians balance efficacy against electrolyte monitoring and the complexity of combination regimens in older patients and those with chronic kidney disease or diabetes.
“The approval of Baxfendy offers a much‑needed, first-in-class innovation for people living with persistently uncontrolled hypertension who have not responded to or tolerated existing medicines,” Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca, said in the press release. “In the US, about 23 million patients are uncontrolled despite being on two or more medicines for hypertension, which is a disease that has seen little therapeutic progress for the past two decades.”1
Sources
